These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25356777)

  • 1. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
    Das K; Lorena PD; Ng LK; Lim D; Shen L; Siow WY; Teh M; Reichardt JK; Salto-Tellez M
    Endocr Relat Cancer; 2010 Sep; 17(3):757-70. PubMed ID: 20519274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.
    Yehia L; Boulos F; Jabbour M; Mahfoud Z; Fakhruddin N; El-Sabban M
    PLoS One; 2015; 10(6):e0129356. PubMed ID: 26046764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer.
    Seok J; Kwak HJ; Kwak Y; Lee M; Park KS; Kim A; Cho SG
    J Transl Med; 2023 Feb; 21(1):129. PubMed ID: 36800968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue.
    Ku JH; Shin JK; Cho MC; Myung JK; Moon KC; Paick JS
    Scand J Urol Nephrol; 2009; 43(6):445-53. PubMed ID: 19968580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
    Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
    Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment.
    Wiebe JP; Souter L; Zhang G
    J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):129-40. PubMed ID: 16806904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
    Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
    Anestis A; Karamouzis MV; Dalagiorgou G; Papavassiliou AG
    Cancer Treat Rev; 2015 Jun; 41(6):547-53. PubMed ID: 25944485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro.
    Tanaka T; Ikegami Y; Nakazawa H; Kuriyama N; Oki M; Hanai J; Sukhatme VP; Kaneki M
    J Cell Physiol; 2017 Jan; 232(1):192-201. PubMed ID: 27137755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
    Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
    Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
    Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
    Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
    Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.